Fears and market moves around the devaluation of China's yuan were an "overreaction," the chief financial officer of the Dutch life sciences group DSM told CNBC.
Geraldine Matchette said Chinese authorities have adequately reassured markets after devaluing the yuan nearly 2 percent in early August.
"There was probably a bit of an overreaction in terms of the currency adjustment," Matchette told CNBC at the World Economic Forum even in Dalian, China on Thursday.
"If we listen more to the communications...from the Chinese authorities it seems that it was much more in terms of a one-time alignment as opposed to a new approach," she added.
August marked a very volatile month not only for the Chinese currency, but for its equity markets, which were on a rollercoaster ride as weak data sent investors running in fear of an overall slowdown in the world's fastest-growing economy.
Matchette said there was likely an "emotional element " in the market moves. "But actually when you step back and think what does it mean for us, it's not as spectacular," she said.
For now, DSM is maintaining its Chinese exposure.
The company reported sales worth $514 million in China during the first half of 2015, compared to $516 million a year earlier. Sales in "high-growth economies," which include China, accounted for 43 percent of DSM's total sales in the 6 months to June.
"The reality for us right now is that it's still a very interesting market. We had good growth last year.
"We're looking carefully to see whether that is changing, but it is not markedly more difficult."